ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2016
Invasive serogroup W
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Geographical and temporal variations of serogroups and clonal types ofJournal of medical microbiology · 2025Article
- Interaction ofFrontiers in cellular and infection microbiology · 2024Article
- Epidemiology of invasive meningococcal disease in Canada, 2012-2019.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- Risk factors for carriage of meningococcus in third-level students in Ireland: an unsupervised machine learning approach.Human vaccines & immunotherapeutics · 2021Article
- Increase in ST-11 serogroup WCanada communicable disease report = Releve des maladies transmissibles au Canada · 2019Article
- A Review of Meningococcal Disease and Vaccination Recommendations for Travelers.Infectious diseases and therapy · 2018Review
- Challenges and opportunities for meningococcal vaccination in the developing world.Human vaccines & immunotherapeutics · 2018Review
- Vaccination strategies for the prevention of meningococcal disease.Human vaccines & immunotherapeutics · 2018Review
- Increase inCanada communicable disease report = Releve des maladies transmissibles au Canada · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIn Ontario, serogroup W
objectiveAll MenW IMD cases in Ontario between January 1, 2009 and June 30, 2016 were reviewed and the
methodsMenW cases were identified in the Integrated Public Health Information System byf Public Health Ontario. MenW isolates were characterized at the National Microbiology Laboratory.
resultsOf the thirteen MenW IMD cases, six were due to isolates typed as sequence type (ST)-22 clonal complex (cc), six were of ST-11 cc, and one ST-167 cc. Most (83%) MenW cases due to the ST-22 cc occurred prior to 2012 while all six MenW cases due to ST-11 cc happened since May 2014. The six MenW ST-11 isolates appeared to be clonal.
conclusionIt appears that a genetic shift in the invasive MenW isolates has occurred in Ontario in 2014 with the ST-11 clone replacing the traditional ST-22 clone.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.